{"id":"sp-shz-tiv","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Injection site soreness or erythema"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1672558","moleculeType":"Small molecule","molecularWeight":"450.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine contains inactivated (killed) influenza virus antigens representing three circulating strains (typically two A subtypes and one B lineage). It works by presenting these antigens to the immune system to generate both humoral (antibody) and cellular immune responses, providing protection against infection by matching strains during the influenza season.","oneSentence":"SP Shz TIV is a trivalent inactivated influenza vaccine that stimulates immune responses against three seasonal influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:47.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT04210349","phase":"PHASE3","title":"Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-01-09","conditions":"Influenza","enrollment":7106},{"nctId":"NCT03344029","phase":"PHASE4","title":"Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-11-03","conditions":"Influenza, Flu","enrollment":1600},{"nctId":"NCT02228980","phase":"PHASE4","title":"Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-09","conditions":"Influenza","enrollment":602}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sanofi Pasteur Shenzhen Trivalent Influenza Vaccine"],"phase":"marketed","status":"active","brandName":"SP Shz TIV","genericName":"SP Shz TIV","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"SP Shz TIV is a trivalent inactivated influenza vaccine that stimulates immune responses against three seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}